Iannini P B, Ehret J, Eickhoff T C
Antimicrob Agents Chemother. 1976 Mar;9(3):448-51. doi: 10.1128/AAC.9.3.448.
Fifty-seven clinical isolates of enterococcus were tested for susceptibility to 10 antibiotics in a microtiter broth dilution system. Amoxicillin, ampicillin, vancomycin, and rifampin inhibited all strains at concentrations easily achievable in blood. Resistance to rifampin developed rapidly. Of the aminoglycosides, gentamicin was most active, followed in decreasing order by tobramycin, amikacin, kanamycin, and streptomycin. High-level resistance to streptomycin was present in 26% of the strains and to kanamycin in 23% of the strains. Growth curve studies of selected strains revealed synergy with ampicillin-amikacin and antagonism with ampicillin-rifampin. It is suggested that ampicillin-gentamicin constitutes adequate initial therapy for enterococcal infections until the results of tests for high-level resistance to kanamycin and streptomycin are known and that clinical trails of ampicillin-amikacin are warranted.
在微量肉汤稀释系统中,对57株肠球菌临床分离株进行了10种抗生素的敏感性测试。阿莫西林、氨苄西林、万古霉素和利福平在血液中易于达到的浓度下可抑制所有菌株。对利福平的耐药性迅速产生。在氨基糖苷类抗生素中,庆大霉素活性最强,其次是妥布霉素、阿米卡星、卡那霉素和链霉素,活性依次降低。26%的菌株对链霉素呈高水平耐药,23%的菌株对卡那霉素呈高水平耐药。对选定菌株的生长曲线研究显示,氨苄西林-阿米卡星组合具有协同作用,而氨苄西林-利福平组合具有拮抗作用。建议在得知对卡那霉素和链霉素高水平耐药的检测结果之前,氨苄西林-庆大霉素可作为肠球菌感染的适当初始治疗方案,并且氨苄西林-阿米卡星的临床试验是有必要的。